DUNEDIN, New Zealand, April 12, 2017 /PRNewswire/ -- Pacific Edge is proud to announce that its recent clinical study on Cxbladder Monitor's clinical performance and utility has been published in the ...

The agreement with FedMed Inc has been finalised with Pacific Edge's subsidiary in the USA, Pacific Edge Diagnostics USA (PED USA). The agreement provides FedMed's contracted insurance carriers, third ...

Providers using BxLink can easily access Cxbladder's suite of tests, allowing faster integration of these groundbreaking diagnostics into everyday practice. The platform's advanced capabilities ensure ...

Pacific Edge Limited (NZX:PEB), a cancer diagnostics company developing and commercializing a suite of non-invasive tests for the detection and management of bladder cancer, announces today the ...

Dunedin-based Pacific Edge has released today the second product in its suite of diagnostic tests for the detection and management of bladder cancer. Cxbladder Triage complements the first molecular ...

Pacific Edge, a cancer diagnostic company, has signed an agreement with FedMed, a provider network in the United States, to make Cxbladder available. The agreement provides FedMed's contracted ...

Bladder cancer is the ninth most common cancer globally and the fifth most common in the United States. Although bladder cancer can often be treated successfully, it has one of the highest recurrence ...

Biomarkers have value in the diagnosis and monitoring of bladder cancer, but their use is still being perfected. The value of using biomarkers in bladder cancer is compelling, though experts in the ...